Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

McKesson : LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson

06/11/2021 | 09:38am EDT

CARY, N.C., June 11, 2021 - Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following at least one prior systemic therapy.

LUMAKRAS, approved by the U.S. Food and Drug Administration (FDA) on May 28th, 2021, is a once daily orally administered KRAS G12C inhibitor. LUMAKRAS was approved through the FDA's Priority Review pathway, which is granted to drugs that are expected to have a large impact on a disease's treatment. This drug was also previously granted Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic NSCLC with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy.

'Prior to LUMAKRAS, patients with NSCLC who progressed beyond first-line treatment had limited treatment options available to them,' said Ashleigh Burdette, senior director of Clinical Innovation at Biologics. 'We are proud to be able to distribute this important therapy and provide high-touch, personalized care to patients.'

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

PR Contact

Claire Crye
Public Relations


McKesson Corporation published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 13:37:03 UTC.

ę Publicnow 2021
02:00pDistributors 'saw everything' as opioid crisis raged, W. Va. county tells cou..
07/26INSIDER TRENDS : McKesson Insider Receives Stock Award, Buy Trend Intact
07/26INSIDER TRENDS : McKesson Insider Receives Stock Award, Trend of Buys Extended
07/26MCKESSON : Submission of Matters to a Vote of Security Holders (Form 8-K)
07/26MCKESSON CORP : Submission of Matters to a Vote of Security Holders, Financial S..
07/26MCKESSON : Hikes Quarterly Dividend by 12% to $0.47 a Share, Payable Oct. 1 to S..
07/26MCKESSON : Raises Quarterly Dividend by 12% to $0.47 Per Share
07/26McKesson Corporation Raises Quarterly Dividend, Payable on October 1, 2021
07/22MCKESSON : Prices, Upsizes Cash Tender Offering to $922.2 Million
07/22MCKESSON CORPORATION : Announces Pricing and Upsizing of Tender Offer
More news
Financials (USD)
Sales 2022 249 B - -
Net income 2022 2 720 M - -
Net Debt 2022 748 M - -
P/E ratio 2022 11,7x
Yield 2022 0,87%
Capitalization 31 320 M 31 320 M -
EV / Sales 2022 0,13x
EV / Sales 2023 0,12x
Nbr of Employees 67 500
Free-Float 57,3%
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 202,50 $
Average target price 222,38 $
Spread / Average Target 9,82%
EPS Revisions
Managers and Directors
Brian Scott Tyler Chief Executive Officer & Director
Britt J. Vitalone Chief Financial Officer & Executive Vice President
Edward A. Mueller Independent Chairman
Nancy Flores Chief Technology & Information Officer, EVP
Donald R. Knauss Independent Director
Sector and Competitors